A Replicating Single-Cycle Adenovirus Vaccine Effective against .

causes nearly 500,000 infections and nearly 30,000 deaths each year in the U.S., which is estimated to cost $4.

Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope.

Most infections occur at mucosal surfaces. Providing a barrier of protection at these surfaces may be a useful strategy to combat the earliest events in infection when there are relatively few pathogens to address. The majority of vaccines are delivered systemically by the intramuscular (IM) route.